Eli Lilly's retatrutide did more than melt fat in TRIUMPH-1. Detailed data presented at the 86th ADA Scientific Sessions on June 6, 2026 showed the triple agonist cut knee osteoarthritis pain by 73.1% and slashed obstructive sleep apnea events by 60.6% — two comorbidities that ride along with obesity and rarely improve this fast on their own. This is the data that turns retatrutide from a weight-loss drug into a multi-indication cardiometabolic franchise.
Research-context information only. Retatrutide is an investigational drug not approved by the FDA. Protocols, doses, and reactions reported below come from published clinical trials. This article reports what has been documented, not what should be done. Possession or use of investigational drugs outside an authorized clinical trial may be illegal in your jurisdiction. Consult a licensed physician for personal medical decisions.
The Basket Trials Inside TRIUMPH-1
TRIUMPH-1 randomized 2,339 adults with obesity (no diabetes) 1:1:1:1 to retatrutide 4 mg, 9 mg, 12 mg, or placebo, dosed once weekly for 80 weeks. Inside that overarching trial, Lilly nested two "basket" sub-studies to test whether the weight loss would carry specific obesity comorbidities with it:
- Knee osteoarthritis basket: 574 participants with symptomatic knee OA
- Obstructive sleep apnea basket: 243 participants with moderate-to-severe OSA
The design matters. Rather than running separate standalone trials, the baskets let Lilly measure pain and sleep-apnea endpoints in the same patients who were also losing weight — building the evidence for label expansions on top of the obesity indication.
Knee Osteoarthritis: 73.1% Pain Reduction
The knee OA basket used the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale, the validated standard in orthopedic and rheumatology trials.
- Baseline WOMAC pain score: 6.0
- Reduction at 80 weeks: 4.3 points
- Percent reduction: 73.1%
A 73% drop in joint-pain scores is the kind of effect usually associated with a dedicated analgesic or joint intervention, not a metabolic drug. It builds on the earlier TRIUMPH-4 knee OA signal (a ~76% reduction reported in December 2025) and confirms the effect replicates in a second, larger cohort. The mechanism is partly mechanical — less body weight means less load on the joint — and partly anti-inflammatory, since GLP-1-class signaling dampens systemic inflammation that drives OA progression.
Obstructive Sleep Apnea: AHI Cut by 60.6%
The OSA basket measured the apnea-hypopnea index (AHI) — the number of breathing interruptions per hour of sleep, the diagnostic backbone of sleep medicine.
- Baseline AHI: 58.6 events/hour (severe range)
- Reduction at 80 weeks: 36.1 events/hour
- Endpoint AHI: ~22.5 events/hour
- Percent reduction: 60.6%
That moves the average participant out of severe sleep apnea (>30 events/hour) and toward the mild-to-moderate range. It puts retatrutide in the same conversation as tirzepatide, which won an FDA sleep-apnea indication in 2024 on similar AHI reductions — except retatrutide is reaching these numbers on the back of substantially larger weight loss.
The Weight Loss That Drives It
None of these comorbidity results happen without the weight loss underneath them. At 80 weeks in TRIUMPH-1, the dose-response was:
| Dose | Weight Loss (80 wk) |
|---|---|
| 12 mg | 28.3% (~70 lb) |
| 9 mg | 25.9% (~64 lb) |
| 4 mg | 19.0% (~47 lb) |
| Placebo | 2.2% |
Nearly half of participants on the top dose (45.3%) lost 30% or more of their body weight. The cardiometabolic cluster moved with it: up to 41% lower triglycerides, 24.2% lower non-HDL cholesterol, 12.3 mm Hg lower systolic blood pressure, and 24.1 cm off the waistline at 80 weeks. The knee-pain and sleep-apnea benefits are the downstream payoff of that weight reduction plus retatrutide's anti-inflammatory and metabolic effects.
Safety Profile
The adverse-event pattern was the familiar incretin-class signature, gastrointestinal-led, with a dose-dependent discontinuation rate: 4.1% (4 mg), 6.9% (9 mg), and 11.3% (12 mg) discontinued for adverse events, versus 4.9% on placebo. The higher dropout at 12 mg is the trade-off for the largest comorbidity benefits — a pattern protocol planners weigh when choosing a target dose.
Dysesthesia — the abnormal skin-tingling sensation unique to retatrutide among the GLP-1-class compounds and tied to its glucagon-receptor arm — continued to appear at low single-digit rates. We covered the mechanism and the community's management approaches in the retatrutide dysesthesia breakdown.
